Oragenics Appoints William “Frank” Peacock MD as Chief Clinical Officer

Core Insights - Oragenics, Inc. has appointed Dr. William "Frank" Peacock as Chief Clinical Officer to lead its Phase II clinical trial for ONP-002, aimed at treating concussions in emergency departments [1][4] - ONP-002 is a new chemical entity designed for intranasal delivery to treat mild Traumatic Brain Injury (mTBI), with a completed Phase I study indicating it is safe and well-tolerated [1][5] - The global incidence of concussions is significant, with an estimated 69 million cases reported annually, highlighting an unmet medical need in this area [6] Company Overview - Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceuticals for neurological disorders and infectious diseases, including treatments for mTBI and Niemann Pick Disease Type C [7] - The company is collaborating with Avance Clinical, a Contract Research Organization (CRO), for its Phase II trial [4] Clinical Development - The Phase II trial for ONP-002 will assess the timing of the first dose, the relationship between drug application and blood biomarker levels, and the evaluation of patient symptom severity shortly after injury [5] - Dr. Peacock's expertise in emergency medicine and blood biomarkers is expected to enhance the success of the clinical trials [4][3]